Comorbidity of metabolic syndrome, diabetes and schizophrenia: Theoretical and practical considerations;A metabolikus szindróma, diabetes mellitus és szkizofrénia komorbiditása: Elméleti és gyakorlati megfontolások

Orvosi Hetilap

Volumn 152, Issue 13, 2011, Pages 505-511

  Réthelyi, János ^a   Sawalhe, Anna Dalal ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

diabetes; insulin resistance; metabolic syndrome; schizophrenia; weight gain

Indexed keywords

ARTICLE; COMORBIDITY; DIABETES MELLITUS; METABOLIC SYNDROME X; SCHIZOPHRENIA;

AGE OF ONSET; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CHRONIC DISEASE; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; FIBRIC ACIDS; FOOD HABITS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INTERDISCIPLINARY COMMUNICATION; LIPIDS; METABOLIC SYNDROME X; RISK REDUCTION BEHAVIOR; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 79952858524     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2011.29079     Document Type: Article

References (36)

1. Stone, M. H.: Szkizofrénia és elozményeinek története. In: A szkizofrénia tankönyve. Eds: Lieberman, J. A., Stroup, T. S., Perkins, D. O. The American Psychiatric Publishing, Washington DC, London, 2006, 1-16.
2. Van Os, J., Kapur, S.: Schizophrenia. Lancet, 2009, 374 , 635-645.
3. Leucht, S., Burkard, T., Henderson, J. és mtsai: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr. Scand., 2007, 116 , 317-333.
4. Bitter I., Jermendy Gy.: Antipszichotikus terápia és metabolikus szindróma - A Magyar Diabetes Társaság Metabolikus Munkacsoportja és a Pszichiátriai Szakmai Kollégium konszenzusértekezlete. Psychiatria Hungarica, 2005, 40 , 312-315.
5. Mód L.: Az antipszichotikumok hisztaminerg mellé khatásai. Adherencia és Pszichiátria, 2010, 1 , 7-13.
6. Fleischhacker, W. W., Cetkovich-Bakmas, M., De Hert, M. és mtsai: Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J. Clin. Psychiatry, 2008, 69 , 514-519.
7. Kurzthaler, I., Fleischhacker, W. W.: The clinical implications of weight gain in schizophrenia. J. Clin. Psychiatry, 2001, 62 , 32-37.
8. McEvoy, J. P., Meyer, J. M., Goff, D. C. és mtsai: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res., 2005, 80 , 19-32.
9. Meyer, J. M., Nasrallah, H. A., McEvoy, J. P. és mtsai: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res., 2005, 80 , 9-18.
10. Kahn, R. S., Fleischhacker, W. W., Boter, H. és mtsai: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, 2008, 371 , 1085-1097.
11. Meyer, J. M., Stahl, S. M.: The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand., 2009, 119 , 4-14.
12. Ryan, M. C., Collins, P., Thakore, J. H.: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry, 2003, 160 , 284-289.
13. Spelman, L. M., Walsh, P. I., Sharifi, N. és mtsai: Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med., 2007, 24 , 481-485.
14. Venkatasubramanian, G., Chittiprol, S., Neelakantachar, N. és mtsai: Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am. J. Psychiatry, 2007, 164 , 1557-1560.
15. Venkatasubramanian, G., Chittiprol, S., Neelakantachar, N. és mtsai: Effect of antipsychotic treatment on insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr. Res., 2010, 119 , 131-137.
16. Van Nimwegen, L. J., Storosum, J. G., Blumer, R. M. és mtsai: Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J. Clin. Endocrinol. Metab., 2008, 93 , 572-577.
17. Lin, P. I., Shuldiner, A. R.: Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr. Res., 2010, 123 , 234-243.
18. Stefansson, H., Ophoff, R. A., Steinberg, S. és mtsai: Common variants conferring risk of schizophrenia. Nature, 2009, 460 , 744-747.
19. De Hert, M., Schreurs, V., Vancampfort, D. és mtsai: Metabolic syndrome in people with schizophrenia: a review. World Psychiatry, 2009, 8 , 15-22.
20. Von Hausswolff-Juhlin, Y., Bjartveit, M., Lindstrom, E. és mtsa: Schizophrenia and physical health problems. Acta Psychiatr. Scand. Suppl., 2009, 438 , 15-21.
21. Leucht, S., Corves, C., Arbter, D. és mtsai: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009, 373 , 31-41.
22. Stahl, S. M., Mignon, L., Meyer, J. M.: Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr. Scand., 2009, 119 , 171-179.
23. Baptista, T., Rangel, N., Fernandez, V. és mtsai: Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr. Res., 2007, 93 , 99-108.
24. Baptista, T., Martinez, J., Lacruz, A. és mtsai: Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can. J. Psychiatry, 2006, 51 , 192-196.
25. Wu, R. R., Zhao, J. P., Guo, X. F. és mtsai: Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am. J. Psychiatry, 2008, 165 , 352-358.
26. Wu, R. R., Zhao, J. P., Jin, H. és mtsai: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA, 2008, 299 , 185-193.
27. Edlinger, M., Ebenbichler, C., Rettenbacher, M. és mtsai: Treatment of antipsychotic-associated hyperglycemia with pioglitazone: a case series. J. Clin. Psychopharmacol., 2007, 27 , 403-404.
28. Cohn, T., Prud'homme, D., Streiner, D. és mtsai: Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry, 2004, 49 , 753-760.
29. Saari, K. M., Lindeman, S. M., Viilo, K. M. és mtsai: A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J. Clin. Psychiatry, 2005, 66 , 559-563.
30. De Hert, M. A., van Winkel, R., Van Eyck, D. és mtsai: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res., 2006, 83 , 87-93.
31. Meyer, J., Loh, C., Leckband, S. G. és mtsai: Prevalence of the metabolic syndrome in veterans with schizophrenia. J. Psychiatr. Pract., 2006, 12 , 5-10.
32. Correll, C. U., Frederickson, A. M., Kane, J. M. és mtsai: Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J. Clin. Psychiatry, 2006, 67 , 575-583.
33. Srisurapanont, M., Likhitsathian, S., Boonyanaruthee, V. és mtsai: Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry, 2007, 7 , 14.
34. Dixon, L., Weiden, P., Delahanty, J. és mtsai: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull., 2000, 26 , 903-912.
35. De Hert, M., van Winkel, R., Van Eyck, D. és mtsai: Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin. Pract. Epidemiol. Ment. Health, 2006, 2 , 14.
36. Allison, D. B., Casey, D. E.: Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry, 2001, 62 , 22-31.